Robert Flavell, MD, PhD
This is a first-in-human, pilot study of the novel PET-imaging radiotracer \[89Zr\]DFO-starPEG. The study is designed to obtain preliminary data to support future development of this agent as an imaging surrogate to visualize enhanced permeability and retention (EPR)-mediated tracer uptake before administration of EPR-based nanomedicines.
PRIMARY OBJECTIVES: I. To descriptively report patterns of \[89Zr\]DFO-starPEG uptake on whole-body PET (Cohorts A \& B). II. To determine the radiation dosimetry following \[89Zr\]DFO-starPEG administration (Cohort A). SECONDARY OBJECTIVES: I. To determine the safety of \[89Zr\]DFO-starPEG (Cohorts A \& B). EXPLORATORY OBJECTIVES: I. To study the pharmacokinetics of \[89Zr\]DFO-starPEG and estimate its half-life (Cohort A). OUTLINE: Participants will be assigned to one of 2 cohorts: * COHORT A: Participants will receive multiple scans over time * COHORT B: Participants will receive a…
Inclusion Criteria: 1. Age \>= 18 years. 2. Histological or cytological confirmation of solid tumor malignancy. 3. Any malignancy, with at least one soft tissue lesion measurable at 1 centimeter (cm) or greater in short axis measurement on cross sectional imaging such as Computerized tomography (CT), Magnetic resonance imaging (MRI), or Positron Emission Tomography (PET)/CT, OR at least 1 lesion which is positive (defined as greater than surrounding background) in the bones on standard of care cancer imaging PET exam. 4. Clinically able to undergo PET/CT imaging. 5. Eastern Cooperative Oncolo…
Given intravenously (IV)
Imaging procedure
Urine and blood specimens will be collected for correlative studies
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.